Biologics: Targets and Therapy (02/18/2016) Vol. 10, P. 17; Caselli, D.; Cesaro, S.; Aricò, M.

Italian researchers conducted a review of available evidence for recombinant human granulocyte colony-stimulating factor (G-CSF) and its biosimilars in the treatment of neutropenia. The fact that the clinical and safety outcomes of the biosimilars are "well within the range of historically reported data for originator filgrastim" highlights the clinical efficacy and safety of biosimilar filgrastim in daily clinical practice, according to the researchers. Biosimilars can contribute to the financial sustainability of treatment programs, the authors note, by providing the opportunity to help lower costs.

Web Link 

Abstract News © 2016 INFORMATION, INC.

Access other Therapeutic Areas:


 

New & Noteworthy